Study offers new hope for babies born with opioid withdrawal syndrome

Researchers are investigating how the proper dosage of a common anti-nausea medication might ease withdrawal symptoms and reduce hospital stays.

2025-04-25

(Press-News.org) As the opioid crisis continues, the number of babies born with neonatal opioid withdrawal syndrome (NOWS) – a condition that affects infants whose mothers used opioids during pregnancy – has risen 5-fold over the past 20 years. According to the Centers for Disease Control (CDC), there are 20,000 infants a year in the United States born with signs of NOWS. These infants often require extended hospital stays and, in some cases, treatment with medications like morphine to relieve withdrawal symptoms.

A new study from Walter Kraft, MD, an internist and clinical pharmacologist at Thomas Jefferson University, and his team further explored the potential of ondansetron, a medication commonly used to treat nausea and considered safe during pregnancy, to help reduce withdrawal symptoms in newborns with NOWS.

The research expands on data from Dr. Kraft's previous work, along with collaborators at Stanford University, of a clinical trial conducted at Jefferson and other sites. That study explored the impact of ondansetron in 90 infants and found that it significantly reduced the severity of withdrawal symptoms.

The current investigation, led by first author Kevin Lam, PharmD, used Bayesian population pharmacokinetic modeling – a mathematical method that describes how different patients process a drug – to identify the concentration of ondansetron that would lead to symptom relief. The model can be used to simulate optimized ondansetron doses.

“In the past, we might have used gut intuition and said, ‘Let’s just double the dose,’” Dr. Kraft said. “Now we can use mathematical modeling to be much more likely to find an effective dose and require fewer patients to enroll in a clinical trial.”

Dr. Kraft, who is also a faculty member at Sidney Kimmel Medical College, says his team is seeking funding for future clinical trials to explore whether ondansetron can reduce the number of symptoms experienced by infants with NOWS or shorten their hospital stay.

“This is a complex medical and societal issue. There’s unlikely to be a single solution," Dr. Kraft said. "We’re optimistic that ondansetron may be part of a multi-pronged approach to improving care for these infants.”

By Queen Muse

END

ELSE PRESS RELEASES FROM THIS DATE:

UT, Volkswagen Group of America celebrate research partnership

2025-04-25

Leadership from the University of Tennessee, Knoxville, Volkswagen Group of America and Oak Ridge National Laboratory celebrated more than a decade of collaboration and the fifth anniversary of the Volkswagen Innovation Hub Knoxville on April 24. Since 2011, UT and Volkswagen have partnered on strategic research projects that have accelerated the discovery and commercialization of new technology, including battery performance, materials science, power electronics and mobility ...

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

2025-04-25

PHILADELPHIA – Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part D introduced by the Inflation Reduction Act (IRA) that took effect in 2025, annual out-of-pocket drug costs for all beneficiaries are now capped at $2,000. However, an overlooked voluntary program that’s part of the IRA could be the key to improving affordability for Medicare patients needing expensive oral cancer drugs, according to a new study from researchers ...

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

2025-04-25

Senescent skin cells, often referred to as zombie cells because they have outlived their usefulness without ever quite dying, have existed in the human body as a seeming paradox, causing inflammation and promoting diseases while also helping the immune system to heal wounds. New findings may explain why: Not all senescent skin cells are the same. Researchers from Johns Hopkins University have identified three subtypes of senescent skin cells with distinct shapes, biomarkers, and functions—an advance that could equip scientists with the ability to target and kill the harmful types while leaving the helpful ones intact. The findings were published today ...

University of Cincinnati Cancer Center presents research at AACR 2025

2025-04-25

University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research Annual Meeting 2025 in Chicago. Study finds contrasting effects of protein on head and neck cancer A small protein called IL-9 has been shown to either contribute to or counteract tumor growth depending on the type of cancer, but its role in head and neck cancer has not been studied. Abstract lead author Sam Nusbaum and her colleagues found IL-9 levels are increased in patients with head and neck cancer compared to healthy controls. “High ...

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

2025-04-25

BOSTON, April 25, 2025 – Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer. The results of these studies, along with dozens of others led by Dana-Farber faculty, will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting held April 25-30, 2025, in Chicago. The institute’s leading experts and researchers will present findings across a spectrum of diseases, underscoring ...

AACR: Researchers share promising results from MD Anderson clinical trials

2025-04-25

ABSTRACTS: CT012, CT132, CT265 CHICAGO, APRIL 25, 2025 ― Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer. In addition to these trials, forthcoming ...

New research explains why our waistlines expand in middle age

2025-04-25

LOS ANGELES — It’s no secret that our waistlines often expand in middle-age, but the problem isn’t strictly cosmetic. Belly fat accelerates aging and slows down metabolism, increasing our risk for developing diabetes, heart problems and other chronic diseases. Exactly how age transforms a six pack into a softer stomach, however, is murky. Now preclinical research by City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, has uncovered the cellular culprit behind age-related abdominal fat, providing new insights into why ...

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

2025-04-25

Researchers from SYSU and IHEP have developed a unique muon veto detector system for TAO, a satellite experiment of the Jiangmen Underground Neutrino Observatory (JUNO). This system features a top veto tracker system with remarkable characteristics such as high light yield, distinct signal-background differentiation and high detection efficiency even at high thresholds, provides the TAO experiment with a robust capability to suppress cosmic muon induced fast neutron and radioisotope events which are significant correlated backgrounds for the neutrino signal. This scalable solution establishes a transferable ...

Chips off the old block

2025-04-25

Using a 3D printer to create organic tissue models that function like living organs may sound like science fiction — but engineers at the University of Pittsburgh are making it reality. Central to their breakthrough is a simple yet powerful idea: when provided with the right environment, cells instinctively know how to organize and function. The key lies in designing scaffolds that mimic the body’s natural structures, giving cells the cues they need to grow, interact, and form tissues. Daniel Shiwarski, assistant professor of bioengineering at the Swanson School of Engineering with a joint appointment at the School of Medicine’s Vascular ...

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

2025-04-25

Background and objectives Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant impairment in quality of life. This study examined the clinical characteristics and surgical outcomes of microvascular decompression combined with nerve combing in patients with ATN. Methods We conducted a retrospective analysis of surgical techniques, clinical data, and treatment outcomes in 40 patients from January 2009 to January 2018. Pain levels ...